Your browser is no longer supported. Please, upgrade your browser.
Aadi Bioscience, Inc.
Index- P/E- EPS (ttm)-6.07 Insider Own0.10% Shs Outstand20.87M Perf Week4.73%
Market Cap585.29M Forward P/E- EPS next Y-2.90 Insider Trans- Shs Float13.46M Perf Month-4.02%
Income-18.50M PEG- EPS next Q-0.66 Inst Own14.50% Short Float0.86% Perf Quarter-8.38%
Sales14.50M P/S40.37 EPS this Y82.30% Inst Trans31.83% Short Ratio1.25 Perf Half Y63.42%
Book/sh11.15 P/B2.44 EPS next Y-47.20% ROA-42.70% Target Price- Perf Year33.38%
Cash/sh1.71 P/C15.90 EPS next 5Y- ROE-45.00% 52W Range14.31 - 49.80 Perf YTD85.10%
Dividend- P/FCF- EPS past 5Y30.90% ROI-14.70% 52W High-45.36% Beta1.50
Dividend %- Quick Ratio16.90 Sales past 5Y- Gross Margin- 52W Low90.13% ATR1.34
Employees12 Current Ratio16.90 Sales Q/Q-100.00% Oper. Margin- RSI (14)43.14 Volatility3.83% 5.54%
OptionableNo Debt/Eq0.00 EPS Q/Q-141.00% Profit Margin- Rel Volume0.51 Prev Close26.78
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume92.16K Price27.21
Recom1.70 SMA20-5.85% SMA50-7.76% SMA2006.75% Volume47,052 Change1.61%
Oct-01-21Initiated Cowen Outperform
Sep-14-21Initiated Ladenburg Thalmann Buy $51
Sep-08-21Initiated Piper Sandler Overweight $45
Oct-06-21 08:00AM  
Sep-20-21 08:30AM  
Sep-13-21 08:00AM  
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, ABI-009 (FYARRO) is a form of sirolimus bound to albumin. Aadi is evaluating ABI-009 in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was founded in 2011 and is headquartered in Pacific Palisades, California.